Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anju Ghangurde

Anju Ghangurde is Scrip's Deputy Asia Editor and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express.  She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.
Advertisement
Set Alert for Articles By Anju Ghangurde

Latest From Anju Ghangurde

Prescription Influencer Shifts In India: Is Pharma Geared Up?

With a broader ecosystem of prescription influencers emerging rapidly in India, pharma needs to engage with these groups extensively, a conference in Mumbai hears.

Commercial Strategy

Novartis Takes Piqray To India With Affordability Pledge

Novartis’s breast cancer therapy Piqray is endorsed by an expert panel for marketing in India and the Swiss company has emphasized its commitment to value-based pricing for the product.

Policy & Regulation India

Zentiva Buys Sanofi's Ankleshwar Site

Zentiva has struck a deal to acquire a manufacturing site in Ankleshwar, India, from its former parent company Sanofi.

Deals Manufacturing

Sanofi India Aligns Manufacturing, Sheds Site To Zentiva

Sanofi sells Indian facility to Zentiva, a key customer for products made at the site, and hopes to make up for the earnings gap through a renewed push for its “core activities and brands.”

India Commercial

Final Salvo? Galvus Infringement Case Simmers In India

Natco has sprung a challenge to Novartis’ vildagliptin patent in India, months before its expiry. The Indian firm will hold back further release of its product on the market amid legal action and it remains to be seen if Novartis will pursue damages.

India Intellectual Property

Mylan's Aflibercept Biosimilar Gets Green Light For Trials In India

Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.

Biosimilars Strategy
See All
Advertisement
UsernamePublicRestriction

Register